MG
CGEM icon

Michael Gelband’s Cullinan Oncology CGEM Stock Holding History

Michael Gelband’s Portfolio CGEM Stock Details CGEM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$520K Buy
+28,537
New +$424K ﹤0.01% 1233
2026
Q1 		– Sell
-30,487
Closed -$316K – 1611
2025
Q4 		$316K Buy
+30,487
New +$275K ﹤0.01% 1302
2025
Q3 		– Sell
-13,988
Closed -$105K – 1581
2025
Q2 		$105K Sell
13,988
-21,212
-60% -$170K ﹤0.01% 1354
2025
Q1 		$266K Buy
35,200
+11,700
+50% +$112K ﹤0.01% 1251
2024
Q4 		$286K Buy
+23,500
New +$338K ﹤0.01% 1289
2024
Q2 		– Sell
-16,347
Closed -$279K – 1572
2024
Q1 		$279K Sell
16,347
-13,290
-45% -$205K ﹤0.01% 1275
2023
Q4 		$302K Sell
29,637
-6,122
-17% -$54.2K ﹤0.01% 1178
2023
Q3 		$324K Sell
35,759
-3,402
-9% -$35.4K ﹤0.01% 1394
2023
Q2 		$421K Sell
39,161
-4,991
-11% -$53K ﹤0.01% 1418
2023
Q1 		$452K Buy
+44,152
New +$487K ﹤0.01% 1364

Other funds holding CGEM

MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Michael Gelband's CGEM Position: Q2 2026 in Review

Michael Gelband opened a new position in Cullinan Oncology (CGEM) in Q2 2026: 28,537 shares worth $520K. The stake represents ﹤0.01% of the portfolio and ranks #1233 among its holdings. This is a return to the name: Michael Gelband previously reported a position in CGEM as recently as Q4 2025.

Michael Gelband first reported a position in CGEM in Q1 2023 and has held it in 10 quarters since. 182 funds tracked by Wall St. Rank hold CGEM as of Q2 2026.

  • Michael Gelband held 28,537 shares of Cullinan Oncology worth $520K as of Q2 2026.
  • Cullinan Oncology was a new Michael Gelband position in Q2 2026.
  • Cullinan Oncology made up ﹤0.01% of Michael Gelband's portfolio in Q2 2026, its #1233 holding.
  • Michael Gelband first reported a position in Cullinan Oncology in Q1 2023 and has held it in 10 quarters since.
  • 182 funds tracked by Wall St. Rank held Cullinan Oncology as of Q2 2026.

Based on ExodusPoint Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.